Arnold Lentnek
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Arnold Lentnek has a total of 16 co-authors. Here are the top co-authors by number of shared publications:
- G. Ralph Corey
Duke University Medical Center, Durham, North Carolina, USA
1 shared publication - John Pullman
Mercury Street Medical Group, Butte MT, USA
1 shared publication - Josep Maria Miró
HIV Unit, Infectious Diseases Service, Hospital Clinic, Barcelona, Spain
1 shared publication - Karl Weiss
Hôpital Maisonneuve-Rosemont, University of Montreal, Montreal, Quebec, Canada H1T 2M4
1 shared publication - Kathleen M. Mullane
University of Chicago
1 shared publication - Mark A. Miller
Jewish General Hospital, Montreal, Quebec, Canada
1 shared publication
Latest Publications
- Open Access
- 23 May 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 289
A randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study
Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). We conducted a randomized, double-blind, Phase 2 trial in patients with uncomplicated S. aureus bacteremia.
- 23 May 2014
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 14 (1) , 289
Open AccessA randomized Phase 2 trial of telavancin versus standard therapy in patients with uncomplicated Staphylococcus aureus bacteremia: the ASSURE study
Staphylococcus aureus bacteremia is a common infection associated with significant morbidity and mortality. Telavancin is a bactericidal lipoglycopeptide active against Gram-positive pathogens, including methicillin-resistant S. aureus (MRSA). We conducted a randomized, double-blind, Phase 2 trial in patients with uncomplicated S. aureus bacteremia.
- Open Access
- 25 March 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 148
Derivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy
Clostridium difficile infection (CDI) continues to be a frequent and potentially severe infection. There is currently no validated clinical tool for use at the time of CDI diagnosis to categorize patients in order to predict response to therapy.
- 25 March 2013
- Published by Springer Nature in BMC Infectious Diseases
- Vol. 13 (1) , 148
Open AccessDerivation and validation of a simple clinical bedside score (ATLAS) for Clostridium difficile infection which predicts response to therapy
Clostridium difficile infection (CDI) continues to be a frequent and potentially severe infection. There is currently no validated clinical tool for use at the time of CDI diagnosis to categorize patients in order to predict response to therapy.